Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose finding in pediatric patients.

G Henze1

  • 1Charité Campus Virchow Klinikum, Berlin, Germany. guenter.henze@charite.de

Ernst Schering Research Foundation Workshop
|November 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

[Age-related characteristics of the efficacy of different glucocorticosteroids in the therapy of acute lymphoblastic leukemia].

Terapevticheskii arkhiv·2015
Same author

Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: A prospective randomised controlled trial.

British journal of anaesthesia·2015
Same author

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Leukemia·2015
Same author

Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.

Leukemia·2015
Same author

Musculoskeletal pain: a new algorithm for differential diagnosis of a cardinal symptom in pediatrics.

Klinische Padiatrie·2014

Pediatric cancer drug safety and effectiveness are not well-established, leading to widespread off-label use. Clinical trials are needed to ensure safe and legal treatments for children with cancer.

Area of Science:

  • Pediatric Pharmacology
  • Oncology
  • Drug Safety

Background:

  • Pharmaceutical product safety and effectiveness in pediatric populations, especially for anti-cancer drugs, remain inadequately established.
  • Established chemotherapy protocols for childhood cancers often involve drugs with contraindications for young children, posing treatment dilemmas.

Purpose of the Study:

  • To highlight the critical gap in established safety and efficacy data for pediatric pharmaceuticals, particularly in oncology.
  • To underscore the prevalence and implications of off-label drug use in pediatric medicine due to lack of licensed alternatives.

Main Methods:

  • Review of existing literature and clinical practices concerning pediatric drug use and off-label prescribing.
  • Analysis of the challenges posed by contraindications in standard pediatric cancer therapies, such as Wilms' tumor treatment.

Related Experiment Videos

Main Results:

  • Off-label prescription rates are high in pediatric settings, ranging from 20% in private practice to over 90% in neonatology.
  • Standard pediatric cancer treatments, like that for Wilms' tumor, rely on drugs with age-related contraindications, necessitating off-label use.

Conclusions:

  • The widespread off-label use of drugs in children is a tolerated but legally questionable practice, driven by a lack of pediatric-specific clinical trials and drug licensing.
  • Urgent need for conducting rigorous clinical trials in pediatric populations to establish safe and effective drug options, ensuring legal and ethical treatment standards.